Tixagevimab with cilgavimab (Evusheld) Access Criteria

Availability of Evusheld

Available evidence indicates that Evusheld is useful against only a small number of the variants of COVID-19 in New Zealand. It is not routinely recommended for use. Pharmac continues to review this regularly and has not proposed changes to the access criteria at this time.

With the criteria on this page, tixagevimab with cilgavimab is available through:

  • Te Whatu Ora – Health New Zealand hospitals
  • primary care providers in the community. 

Te Whatu Ora manages the community availability of tixagevimab with cilgavimab. Further details of the ordering and administration process is available on Te Whatu Ora's website(external link).

Further detail of the fees and claiming process for the administration of tixagevimab with cilgavimab in primary care can be requested from your primary health organisations or district portfolio manager.

Tixagevimab with cilgavimab (Evusheld) access criteria

Indication – Pre-exposure prophylaxis or treatment of COVID-19

Access criteria - Any relevant practitioner. 

Approvals are valid for patients where the prescribing clinician confirms the patient meets the following criteria and has endorsed the prescription accordingly:

All of the following: 


* potent B-cell or T-cell depleting therapy such as rituximab, obinutuzumab, ocrelizumab, bendamustine, fludarabine, cladribine, alemtuzumab, anti-thymocyte globulin, CamPath antibody treatment, anti-B-cell bispecific antibody, CAR T-cells or BiTE antibody treatment 

Funded dosing:

  1. Medsafe has provisionally approved Evusheld for pre-exposure prophylaxis at a dose of 300mg IM (150mg tixagevimab and 150mg cilgavimab).
  2. Maximum funded single dose of 600mg IM (300mg tixagevimab and 300 mg cilgavimab) permitted for pre. This dose is unapproved and under consideration by Medsafe.
  3. Repeat dosing not currently funded, this remains under consideration.
  4. Evusheld for use in treatment of COVID-19 infection is unapproved and under consideration by Medsafe.